Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick Place in Chicago. The studies include LUN14-179 (poster session and discussion), GU14-206 (poster session and discussion), and GI14-186 (poster session).

LUN14-179

Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179. See abstract.

• • Type 1: Poster Session
  • Time: Saturday June 3, 8:00 AM to 11:30 AM
  • Location: Hall A

• • Type 2: Poster Discussion Session
  • Time: Saturday June 3, 1:15 PM to 2:30 PM
  • Location: Hall D2
•  
  • Abstract Number: 8523
  • Poster Board Number: 259
  • Citation: J Clin Oncol 35, 2017 (suppl; abstr 8523)
  • Author(s): Greg Andrew Durm, Cynthia Johnson, Shadia Ibrahim Jalal, Ahad Ali Sadiq, Salma Jabbour, Robin Zon, Goetz H. Kloecker, Karen L. Reckamp, William B. Fisher, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Department of Biostatistics, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Michiana Hematology Oncology, PC, South Bend, IN; University of Louisville, Louisville, KY; City of Hope Comprehensive Cancer Center, Duarte, CA; Medical Consultants, Muncie, IN

GU14-206

A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients with incurable platinum refractory germ cell tumors: Hoosier Cancer Research Network GU14-206. See abstract.

• • Type 1: Poster Session
  • Time: Sunday June 4, 8:00 AM to 11:30 AM
  • Location: Hall A
•  
  • Type 2: Poster Discussion Session
  • Time: Sunday June 4, 11:30 AM to 12:45
  • Location: Arie Crown Theater
•  
  •  Abstract Number: 4520
  • Poster Board Number: 198
  • Citation: J Clin Oncol 35, 2017 (suppl; abstr 4520)
  • Author(s): Nabil Adra, Sandra K. Althouse, Natraj Reddy Ammakkanavar, Milan Radovich, Costantine Albany, David J. Vaughn, Lawrence H. Einhorn, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Community Cancer Center, Indianapolis, IN; Abramson Cancer Center, Philadelphia, PA

GI14-186

A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: Hoosier Cancer Research Network GI14-186. See abstract.

• • Type: Poster Session
  • Time: Saturday June 3, 8:00 AM to 11:30 AM
  • Location: Hall A
  • Abstract Number: 3541
  • Poster Board Number: 164
  • Citation: J Clin Oncol 35, 2017 (suppl; abstr 3541)
  • Author(s): Safi Shahda, Anne M. Noonan, Tanios S. Bekaii-Saab, Bert H. O’Neil, Amikar Sehdev, Walid Labib Shaib, Paul R. Helft, Patrick J. Loehrer, Yan Tong, Ziyue Liu, Bassel F. El-Rayes; Indiana University, Indianapolis, IN; The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH; Mayo Clinic Cancer Center, Phoenix, AZ; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Winship Cancer Institute, Atlanta, GA; Indiana University School of Medicine, Indianapolis, IN

Attending ASCO? Stop by the HCRN Booth (#25099) in McCormick Place South, Exhibit Hall A.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 160 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 5,000 subjects have participated in Hoosier Cancer Research Network clinical trials.